INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///
ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
  • 11/01/2023

    Tempus Announces Eight Abstracts Accepted For Presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting

    Tempus, a leader in artificial intelligence and precision medicine, today announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023.  "We continue to be a leader in the advancement of immunotherapy research, as evidenced...

  • 10/20/2023

    Tempus Announces Five Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2023

    Tempus, a leader in artificial intelligence and precision medicine, today announced five abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2023, which convenes in Madrid, Spain, from October 20-24, 2023.  "We are excited to share our latest research at ESMO this year, as we continue to make our precision medici...

  • 08/22/2023

    Tempus Welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ Community

    Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers t...

  • 08/15/2023

    FDA Grants Breakthrough Device Designation To Tempus’ HLA-LOH Companion Diagnostic Test

    Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its HLA-LOH assay as a companion diagnostic (CDx) test. The test uses a machine learning model to analyze sequence data produced b...

  • 07/12/2023

    Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

    Study aims to create the most robust, multi-omic dataset for patients with NSCLC Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset...

  • 07/06/2023

    Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

    Diagnostic will be used to prospectively assess HLA loss in patients’ tumors and guide appropriate treatment selection in TScan’s solid tumor clinical trial Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical...

  • 06/21/2023

    Tempus Launches Standalone RNA Sequencing Test, xR

    Tempus, a leader in artificial intelligence and precision medicine, today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. Tempus has always understood the importa...

  • 06/02/2023

    Tempus Exhibits 20 Abstracts at the 2023 American Society of Clinical Oncology Annual Meeting

    Tempus, a leader in artificial intelligence and precision medicine, today announced the company will exhibit 20 abstracts at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from June 2-6, in Chicago, Illinois. This year, Tempus is presenting its latest research via two oral presentations, one poster discussion session, and...

  • 06/01/2023

    Tempus Announces Broad Launch of Tempus One

    AI-enabled clinical assistant provides access to patient insights directly at your fingertips Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the upcoming broad launch of Tempus One – the first, AI-enabled clinical assistant that leverages advancements in generative AI to provide clinicians access to patient insights directly at...

  • 05/10/2023

    Tempus Announces Dr. Ned Sharpless as a Senior Strategic Advisor

    Tempus, a leader in artificial intelligence and precision medicine, today announced that Norman E. “Ned” Sharpless, MD, will serve as a senior strategic advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and cancer researcher to further the company’s mission...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18